{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:46:20Z","timestamp":1765547180498,"version":"3.30.1"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>Drugs that target factor XI and\/or XIa have been evaluated as alternatives to existing anticoagulants, in light of studies that indicate that a decrease in Factor XI\/XIa levels or activity may result in a lower risk of thrombosis without a significant increase in bleeding risk. Milvexian is an investigational small-molecule factor XIa inhibitor that has recently completed phase 2 clinical trials. Preclinical studies were suggestive of its potential to prevent arterial and venous thrombosis. It was well-tolerated in healthy participants, as well as in participants with mild or moderate hepatic impairment and moderate or severe renal impairment. Notably, patients who received milvexian after knee arthroplasty had a dose-proportional lower incidence of venous thromboembolism compared to patients who received postoperative enoxaparin, and they had a lower incidence of clinically relevant bleeding. A separate phase 2 trial was conducted that assessed the use of milvexian for secondary stroke prevention in patients who had ischemic stroke or transient ischemic attack. It failed its primary objective of establishing a dose-response relationship between milvexian and a composite endpoint of symptomatic ischemic stroke or covert brain infarction. The trial did, however, show a reduction in the relative risk of symptomatic ischemic stroke across most of the treatment groups receiving various dosages of milvexian compared to placebo. The efficacy of milvexian in secondary stroke prevention will be further assessed in an upcoming phase 3 trial. Additional upcoming phase 3 trials will also assess its efficacy in stroke prevention in patients with atrial fibrillation as well as in event reduction in patients with acute coronary syndrome.<\/jats:p>","DOI":"10.1097\/crd.0000000000000588","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T14:05:27Z","timestamp":1706882727000},"page":"93-97","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Milvexian: A Focus on a New Oral Anticoagulant that Targets Factor XIa for Thromboembolism Prophylaxis"],"prefix":"10.1097","volume":"33","author":[{"given":"Joseph","family":"Birchansky","sequence":"first","affiliation":[{"name":"Cayuga Medical Center, Ithaca, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Cardiology, New York Medical College, Westchester Medical Center, Valhalla, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,2,2]]},"reference":[{"key":"R1-20241205","doi-asserted-by":"crossref","first-page":"7425","DOI":"10.1021\/acs.jmedchem.8b00173","article-title":"Factor XIa inhibitors as new anticoagulants.","volume":"61","author":"Quan","year":"2018","journal-title":"J Med Chem"},{"key":"R2-20241205","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.kint.2021.08.028","article-title":"Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target.","volume":"100","author":"Eikelboom","year":"2021","journal-title":"Kidney Int"},{"key":"R3-20241205","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1021\/acs.jmedchem.1c00613","article-title":"Discovery of milvexian, a high-affinity, orally bioavailable inhibitor of factor xia in clinical studies for antithrombotic therapy.","volume":"65","author":"Dilger","year":"2022","journal-title":"J Med Chem"},{"key":"R4-20241205","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1161\/CIRCULATIONAHA.122.062353","article-title":"Pharmacology and clinical development of factor XI inhibitors.","volume":"147","author":"Greco","year":"2023","journal-title":"Circulation"},{"key":"R5-20241205","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jacc.2022.11.057","article-title":"Clinical evaluation of factor XIa inhibitor drugs.","volume":"81","author":"Harrington","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"R6-20241205","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1161\/CIRCULATIONAHA.122.061132","article-title":"What is the future of factor XI inhibitors?","volume":"146","author":"Weitz","year":"2022","journal-title":"Circulation"},{"key":"R7-20241205","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1160\/TH10-05-0307","article-title":"Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis.","volume":"105","author":"Saloman","year":"2011","journal-title":"Thromb Haemost"},{"key":"R8-20241205","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1182\/blood-2007-10-120139","article-title":"Reduced incidence of ischemic stroke in patients with severe factor XI deficiency.","volume":"111","author":"Saloman","year":"2008","journal-title":"Blood"},{"key":"R9-20241205","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1056\/NEJM200003093421004","article-title":"High levels of coagulation factor XI as a risk factor for venous thrombosis.","volume":"342","author":"Meijers","year":"2000","journal-title":"N Eng J Med"},{"key":"R10-20241205","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1309\/QC259F09UNMKVP0R","article-title":"Elevated factor XI activity levels are associated with an increased odds ratio for cerebrovascular events.","volume":"126","author":"Yang","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"R11-20241205","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1111\/j.1538-7836.2010.04031.x","article-title":"Coagulation factor XI as a novel target for antithrombotic treatment.","volume":"8","author":"L\u00f6wenberg","year":"2010","journal-title":"J Thromb Haemost"},{"key":"R12-20241205","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1538-7836.2012.04653.x","article-title":"Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European network of rare bleeding disorders.","volume":"10","author":"Peyvandi","year":"2012","journal-title":"J Thromb Haemost"},{"key":"R13-20241205","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/jth.15588","article-title":"Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor XIa: in vitro studies and in vivo evaluation in experimental thrombosis in rabbits.","volume":"20","author":"Wong","year":"2022","journal-title":"J Thromb Haemost"},{"key":"R14-20241205","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood.2021011725","article-title":"The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial.","volume":"138","author":"Lorentz","year":"2021","journal-title":"Blood"},{"key":"R15-20241205","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ekir.2021.11.011","article-title":"Phase 2 study of the factor XI antisense inhibitor IONIS-FXIRx in patients with ESRD.","volume":"7","author":"Walsh","year":"2022","journal-title":"Kidney Int Rep"},{"key":"R16-20241205","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis.","volume":"372","author":"B\u00fcller","year":"2015","journal-title":"N Eng J Med"},{"key":"R17-20241205","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2019.20687","article-title":"Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial.","volume":"323","author":"Weitz","year":"2020","journal-title":"JAMA"},{"key":"R18-20241205","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism.","volume":"385","author":"Verhamme","year":"2021","journal-title":"N Eng J Med"},{"key":"R19-20241205","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0140-6736(22)01588-4","article-title":"Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial.","volume":"400","author":"Shoamanesh","year":"2022","journal-title":"Lancet"},{"key":"R20-20241205","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"key":"R21-20241205","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.122.061612","article-title":"A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction.","volume":"146","author":"Rao","year":"2022","journal-title":"Circulation"},{"key":"R29-20241205","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/cts.13148","article-title":"First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor.","volume":"15","author":"Perera","year":"2022","journal-title":"Clin Transl Sci"},{"key":"R30-20241205","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1038\/s41598-022-08768-y","article-title":"Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants.","volume":"12","author":"Perera","year":"2022","journal-title":"Sci Rep"},{"key":"R31-20241205","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s40262-022-01110-9","article-title":"Single-Dose pharmacokinetics of Milvexian in participants with mild or moderate hepatic impairment compared with healthy participants.","volume":"61","author":"Perera","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"R32-20241205","doi-asserted-by":"crossref","first-page":"22239","DOI":"10.1038\/s41598-022-25936-2","article-title":"Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitor.","volume":"12","author":"Perera","year":"2022","journal-title":"Sci Rep"},{"key":"R33-20241205","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s40119-022-00266-6","article-title":"Effects of itraconazole and diltiazem on the pharmacokinetics and pharmacodynamics of Milvexian, a factor xia inhibitor.","volume":"11","author":"Perera","year":"2022","journal-title":"Cardiol Ther"},{"key":"R34-20241205","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s40262-022-01150-1","article-title":"Single-Dose pharmacokinetics of milvexian in participants with normal renal function and participants with moderate or severe renal impairment.","volume":"61","author":"Perera","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"R35-20241205","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism.","volume":"385","author":"Weitz","year":"2021","journal-title":"N Eng J Med"},{"key":"R36-20241205","doi-asserted-by":"crossref","first-page":"106742","DOI":"10.1016\/j.jstrokecerebrovasdis.2022.106742","article-title":"Rationale and design of the AXIOMATIC-SSP phase II trial: antithrombotic treatment with factor XIa inhibition to optimize management of acute thromboembolic events for secondary stroke prevention.","volume":"31","author":"Sharma","year":"2022","journal-title":"J Stroke Cerebrovasc Dis"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000588","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T21:01:09Z","timestamp":1733432469000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,2]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000588","relation":{},"ISSN":["1538-4683"],"issn-type":[{"type":"electronic","value":"1538-4683"}],"subject":[],"published":{"date-parts":[[2024,2,2]]}}}